clinical trial · NCT06525246
Study of ONO-7475 in Combination With Osimertinib in EGFR Gene Mutation-positive Non-small Cell Lung Cancer
Ono Pharmaceutical Co., Ltd.·phase1·completed·n = 78
Stage IIIB Non-small Cell Lung CancerStage IIIC Non-Small Cell Lung CancerStage IV Non-small Cell Lung CancerRecurrent Non-Small Cell Lung CancerEGFR Mutation-Related TumorsONO-7475Osimertinib Mesylate
brief summary
This study is to evaluate the tolerability and safety of ONO-7475 in combination with osimertinib in the first-line treatment of patients with EGFR-mutated, stage IIIB/IIIC/IV or recurrent non-small cell lung cancer (NSCLC), which is unsuitable for radical irradiation.
started
Aug 6, 2021
primary completion
Jun 23, 2025
completion
Jun 23, 2025
last updated
Mar 13, 2026
official title
ONO-7475-03: ONO-7475 Phase I Study An Open-label, Uncontrolled Study of ONO-7475 in Combination With Osimertinib in EGFR Gene Mutation-positive Non-small Cell Lung Cancer
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol